---
title: "MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289054333.md"
description: "MediciNova announced it received a Notice of Allowance from the USPTO for a patent covering the use of MN-166 (ibudilast) in combination with anti-PD-1 immune checkpoint inhibitors for treating glioblastoma. This development strengthens the company's intellectual property portfolio as it advances its strategy for developing combination therapies."
datetime: "2026-06-08T12:02:46.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289054333.md)
  - [en](https://longbridge.com/en/news/289054333.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289054333.md)
generator: "portal-rs"
---

# MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment

On June 8, 2026, in La Jolla, California, MediciNova, Inc., a biopharmaceutical company listed on NASDAQ (MNOV) and the Tokyo Stock Exchange (Code Number: 4875), announced receiving a Notice of Allowance from the U.S. Patent and Trademark Office. This notice pertains to a patent application involving the utilization of ibudilast (MN-166) alongside an immune checkpoint inhibitor, specifically an anti-PD-1 antibody, for treating glioblastoma. The allowance of this patent is anticipated to reinforce the company's intellectual property position as it advances its strategy for developing combination therapies.

### Related Stocks

- [MNOV.US](https://longbridge.com/en/quote/MNOV.US.md)
- [4875.JP](https://longbridge.com/en/quote/4875.JP.md)

## Related News & Research

- [This Paymentus Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday](https://longbridge.com/en/news/299315383.md)
- [MediciNova says US patent office allows ibudilast–anti-PD-1 combo claims for glioblastoma treatment](https://longbridge.com/en/news/291279545.md)
- [MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast) | MNOV Stock News](https://longbridge.com/en/news/287687352.md)
- [MediciNova says SEANOBI-ALS expanded-access study of MN-166 reaches 200-patient enrollment target](https://longbridge.com/en/news/292763424.md)
- [MediciNova CEO Iwaki base salary rises to $690,246 under new employment agreement](https://longbridge.com/en/news/296348115.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**